In this case, the CSN identifies and presents complaints (depression) that might have pharmacologic root cause (serotonergic burden) likely due to a CYP2D6 variant rendering the patient a poor metabolizer of ondansetron and cyclobenzaprine. This evidence concerns the gene CYP2D6 and depressive disorder.